The FDA has accepted a Biologics License Application for imsidolimab to treat generalized pustular psoriasis, a rare inflammatory skin condition.
Imsidolimab is a monoclonal antibody that inhibits interleukin-36 receptor signaling and is administered intravenously.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for imsidolimab ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
US FDA accepts Vanda Pharmaceuticals’ BLA for imsidolimab to treat Generalized Pustular Psoriasis: Washington Friday, February 27, 2026, 17:00 Hrs [IST] Vanda Pharmaceuticals In ...
Vanda Pharmaceuticals VNDA shares are up during Wednesday’s premarket session following the FDA’s approval of Bysanti, a new ...
A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.
Bruker Corporation announced the launch of CellScapetm XR, a next-generation spatial proteomics platform designed to advance ...
ENNOVI today announced the release of its Sustainability Report 2024, which highlights a year of strong external recognition for its sustainability performance, transparency and governance; ...
Asianet Newsable on MSN
VNDA stock soars 40% overnight after Bysanti approval: What’s the next catalyst and how much upside remains?
Vanda said it expects Bysanti to be available in the market in the third quarter of 2026.
Detailed price information for Vanda Pharmaceuticals (VNDA-Q) from The Globe and Mail including charting and trades.
Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results